Peer Review History

Original SubmissionFebruary 12, 2021
Decision Letter - Rashidul Alam Mahumud, Editor

PONE-D-21-04831

Quality assured implementation of the Slovenian breast cancer screening programme

PLOS ONE

Dear Dr. Krajc,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please insert comments here and delete this placeholder text when finished. Be sure to:

Please revise your manuscript to address the reviewer's comments.

Please submit your revised manuscript by Jul 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Rashidul Alam Mahumud, MPH, MSc, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

  1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this article, women aged 50-69 are invited. But in US GUIDELINES, they recommend 45-74 years women to screen. I think it would be better to screen earlier as breast cancer is quite common before 50 years.

You should give training to women how to carry out breast self examination(BSE),it can help them to be alert to any abnormalities in their breast. Thereby you can assess the high risk group without doing mammography for all.

Because mammography screening may cause harms, the most widely discussed being the over diagnosis. False positive results affecting one in every five women.

Reviewer #2: Review report

Title: Quality assured implementation of the Slovenian breast cancer screening programme

ID: PONE-D-21-04831

Comments: This article comprehends the details of Slovenian breast cancer screening programme. The authors outline various phases of the programme ranging from organization level to implementation stage. As a reviewer, I believe that the effort is notable mainly because it summarizes particulars of a successful nationwide programme targeting a major health concern in women population. The publication of such an article at reputed forum of PLOS will certainly attract wider range of relevant audience. The structure of the programme at patient level is simple, designed, flexible and thus remains workable in different socio-economic backgrounds. For replication purposes, in some other parts of the world, the details of this kind of programme deserve to be publishable (in reviewer’s opinion).

Here are some specific observations of the reviewer.

• Unnecessary lengthy sentences, for example lines 61-67, 121-125 are sample of the issue.

• Sentence structure needed to be more cohesive. As this article details the phases of a very delicate programme; the massage must be very clear and well posed. On the contrary, authors after all the hard work of assembling details of the programme seems little tired at writing stage. Some of the examples are, lines 48-55, 152-155, 208-214 etc. In general authors are trying to comprehend huge amount of information in single sentence. This is observable as a pattern in the writing and seriously compromises the significance of the work.

• The reviewer encourages to use mathematical expressions when necessary. Especially, in data analysis section where vital statistics such as coverage by invitation, programme extension etc. are discussed for the first time.

• It seems better to provide the list of EU performance guidelines to document the performance indicators.

I hope the observations will be helpful in enhancing the quality of the good work conducted by the authors.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

We would like to thank the Reviewers for their thoughtful comments.

We have addressed all of the following comments point by point and have revised the original manuscript using the Track Changes function (see file 'Revised Manuscript with Track Changes').

As requested, we have revised and uploaded the manuscript taking into account the journal requirements and the comments of the reviewers. Please find below copies of the comments received and our respective responses to each issue.

Sincerely,

Mateja Krajc, corresponding author

mkrajc@onko-i.si

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: The revised manuscript adheres to the journal’s style requirements.

2. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research<http://journals.plos.org/plosone/s/submission-guidelines%23loc-human-subjects-research>.

Response: Screening participants provide informed consent for use of their data for research, and quality assurance of the programme, which includes reporting and publication of aggregate results. Only aggregate, anonymized data was accessed for the preparation of the manuscript. This information has been added to the manuscript (line 98-99: see file 'Revised Manuscript with Track Changes').

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: Table 1 contains the minimal data set upon which the present study is based. The data source (Breast Cancer Screening Registry DORA) is stated under the table (line 335).

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1.-3.

No Response requested.

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

Response: In the finalization of the manuscript, two native English speakers have performed a thorough language revision. These changes are too numerous to mention by line.

________________________________________

5. Review Comments to the Author

Reviewer #1: In this article, women aged 50-69 are invited. But in US GUIDELINES, they recommend 45-74 years women to screen. I think it would be better to screen earlier as breast cancer is quite common before 50 years.

Response: The current age range of the Slovenian Breast Cancer Screening Programme was adopted during the planning phase based on the European Council recommendation on cancer screening published in 2003 (reference No.15 in the manuscript). At the time, this EU policy document was unanimously approved by the health ministers of the EU member states.

We anticipate that the Slovenian programme will expand the screening age range if an expansion is recommended in the upcoming review of the 2003 EU council recommendation in the framework of the new EU action plan on cancer (https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf).

You should give training to women how to carry out breast self examination (BSE), it can help them to be alert to any abnormalities in their breast. Thereby you can assess the high risk group without doing mammography for all.

Response: In Slovenia BSE is recommended for all women. Nurses in primary care educate women about breast awareness as a means to avoid unnecessary delay in case finding and clinical diagnosis, but not as a substitute for population-based, quality-assured breast cancer screening. The Slovenian screening programme also recommends BSE between two screening examinations. This information is published on the screening website and written in the screening booklet. Letters informing women of their normal screening results also include a recommendation to perform BSE in the interval between two screening mammographies. (lines 184-187).

Because mammography screening may cause harms, the most widely discussed being the over diagnosis. False positive results affecting one in every five women.

Response: We agree that mammography screening may cause harms. The DORA program was set up to minimise harms and maximize benefits through a commitment to quality assurance. In communication with women the programme emphasizes the need to achieve an appropriate balance between the potential harms and benefits of breast cancer screening. This statement has been added to the manuscript (lines 151-153).

Reviewer #2: Review report

Title: Quality assured implementation of the Slovenian breast cancer screening programme

ID: PONE-D-21-04831

Comments: This article comprehends the details of Slovenian breast cancer screening programme. The authors outline various phases of the programme ranging from organization level to implementation stage. As a reviewer, I believe that the effort is notable mainly because it summarizes particulars of a successful nationwide programme targeting a major health concern in women population. The publication of such an article at reputed forum of PLOS will certainly attract wider range of relevant audience. The structure of the programme at patient level is simple, designed, flexible and thus remains workable in different socio-economic backgrounds. For replication purposes, in some other parts of the world, the details of this kind of programme deserve to be publishable (in reviewer’s opinion).

Here are some specific observations of the reviewer.

• Unnecessary lengthy sentences, for example lines 61-67, 121-125 are sample of the issue.

Response: In the language revision (see our response to Comment 4. above) we have shortened unduly long sentences in the suggested lines.

• Sentence structure needed to be more cohesive. As this article details the phases of a very delicate programme; the massage must be very clear and well posed. On the contrary, authors after all the hard work of assembling details of the programme seems little tired at writing stage. Some of the examples are, lines 48-55, 152-155, 208-214 etc. In general authors are trying to comprehend huge amount of information in single sentence. This is observable as a pattern in the writing and seriously compromises the significance of the work.

Response: Sentence structure has been corrected as suggested.

• The reviewer encourages to use mathematical expressions when necessary. Especially, in data analysis section where vital statistics such as coverage by invitation, programme extension etc. are discussed for the first time.

Response: We have added the formulas for programme extension, and for coverage and participation rates, to the respective column headings in Table 1.

• It seems better to provide the list of EU performance guidelines to document the performance indicators.

I hope the observations will be helpful in enhancing the quality of the good work conducted by the authors.

Response: The full list of EU guidelines performance indicators is provided in reference [6]. Those performance indicators that are regularly monitored by the programme have been added to the text under the heading “Performance indicators” in the “Materials and Methods” section (lines 256-265). In the “Results” section we also explain in greater detail which recommended levels of coverage have been consistently exceeded in recent years (lines 340-344).

Decision Letter - Rashidul Alam Mahumud, Editor

Quality assured implementation of the Slovenian breast cancer screening programme

PONE-D-21-04831R1

Dear Dr. Krajc,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rashidul Alam Mahumud, MPH, MSc, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Subject: Review Report for the Article entitled “Quality assured implementation of the Slovenian breast cancer screening programme”. Manuscript I. D. PONE-D-21-04831R1

Dear Editor-in-Chief

PLOS ONE,

The quality of the manuscript has significantly improved after revision. I as a reviewer think that the article is consistent with the standards of the Journal. The publication of the details of such public health initiatives, in my opinion, always remain useful on multiple fronts and the usefulness become more noticeable when it is published on reputed forum like PLOS. I recommend this article for publication, and it was a pleasure to read it first hand.

Thanks and Regards

Abdu R Rahman

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Formally Accepted
Acceptance Letter - Rashidul Alam Mahumud, Editor

PONE-D-21-04831R1

Quality assured implementation of the Slovenian breast cancer screening programme

Dear Dr. Krajc:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rashidul Alam Mahumud

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .